USPTO serial 90392963
GALENAGEN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MASULLO, MARCO
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GALENAGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicole K. McLaughlin
Nicole K. McLaughlin DUANE MORRIS LLP30 SOUTH 17TH STREETPHILADELPHIA, PA 19103-4196United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders | ACTIVE | — |
| 042 | Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body | ACTIVE | — |
| 044 | Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Galenagen, LLC
- Other trademarks owned by Galenagen, LLC
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GALENAGEN
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 11, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 11, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 3, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 2, 2024 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Apr 2, 2024 | EXT5 | SOU EXTENSION 5 FILED | — |
| Apr 2, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 4, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 2, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 2, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 2, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 31, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 29, 2023 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 29, 2023 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 29, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 4, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 30, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 30, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 30, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 30, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 28, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 28, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 5, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 10, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 10, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 21, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 14, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 22, 2020 | NWAP | NEW APPLICATION ENTERED | — |